Chairman & Chief Executive Officer
Chairman & Chief Executive Officer
Ian C. Read is Chairman of the Board and Chief Executive Officer of Pfizer, one of the world’s premier innovative biopharmaceutical companies, which brings therapies to patients that significantly improve their lives. These include medicines, vaccines, and many of the world’s best-known consumer healthcare products.
Prior to being named CEO in December, 2010, Ian served as group president of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units: Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.
Ian began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions in a number of Pfizer’s largest and fastest-growing operations, including Chief Financial Officer of Pfizer Mexico, and Country Manager of Pfizer Brazil. In 1996, he was appointed president of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. Ian became Executive Vice President, Europe, in 2000; was named a Corporate Vice President in 2001; and assumed responsibility for Canada and Europe in 2002. He later became accountable for operations in Pfizer’s Africa/Middle East region and Latin America.
Ian received his B.Sc. in chemical engineering from London University Imperial College in 1974. He earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales in 1978.
Ian serves on the boards of PhRMA, Kimberly-Clark, and the Partnership for New York City.
CEO Roundtable on Cancer
Charles A. Sanders Life Sciences Award Winner
CEO Cancer Gold Standard™
Gold Standard Employer
At Pfizer we are committed to wellness through helping colleagues and patients find treatments and cures, and advancing the goal of preventing illness. The CEO Cancer Gold Standard is one way to help colleagues and their family members take responsibility for their health.
Gold Standard Task Force Participation
Task Force Member(s): Nicole Shaffer, DNP, CRNP-BC, COHN-S, FAAO, Director, Occupational Health & Wellness
Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Mace L. Rothenberg, MD, Chief Development Officer for Oncology, Global Product Development Group, Pfizer
Project Data Sphere, LLC
Pioneering Data Provider
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.